Sciencast Management LP Buys New Position in MAXIMUS, Inc. (NYSE:MMS)

Sciencast Management LP purchased a new position in MAXIMUS, Inc. (NYSE:MMS) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 7,200 shares of the health services provider’s stock, valued at approximately $504,000.

A number of other large investors also recently added to or reduced their stakes in the stock. Norges Bank bought a new stake in shares of MAXIMUS during the fourth quarter valued at approximately $56,359,000. Mackenzie Financial Corp boosted its holdings in shares of MAXIMUS by 21.9% during the 1st quarter. Mackenzie Financial Corp now owns 2,067,283 shares of the health services provider’s stock valued at $120,316,000 after buying an additional 371,567 shares in the last quarter. Copeland Capital Management LLC bought a new stake in MAXIMUS during the first quarter worth about $12,963,000. Schroder Investment Management Group increased its stake in shares of MAXIMUS by 250.9% during the first quarter. Schroder Investment Management Group now owns 213,512 shares of the health services provider’s stock valued at $12,546,000 after purchasing an additional 152,672 shares in the last quarter. Finally, Amundi Pioneer Asset Management Inc. lifted its holdings in shares of MAXIMUS by 7,431.9% during the first quarter. Amundi Pioneer Asset Management Inc. now owns 148,680 shares of the health services provider’s stock valued at $10,553,000 after purchasing an additional 146,706 shares during the last quarter. Institutional investors and hedge funds own 94.80% of the company’s stock.

In related news, Vice Chairman Richard A. Montoni sold 10,466 shares of MAXIMUS stock in a transaction on Tuesday, June 9th. The stock was sold at an average price of $72.84, for a total transaction of $762,343.44. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Vice Chairman Richard A. Montoni sold 31,398 shares of the business’s stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $67.91, for a total value of $2,132,238.18. The disclosure for this sale can be found here. Insiders own 2.00% of the company’s stock.

Shares of NYSE MMS opened at $74.21 on Friday. The firm’s 50-day moving average price is $70.64 and its 200-day moving average price is $67.94. The company has a quick ratio of 1.97, a current ratio of 1.97 and a debt-to-equity ratio of 0.13. The company has a market cap of $4.55 billion, a PE ratio of 22.90 and a beta of 0.93. MAXIMUS, Inc. has a 52-week low of $46.42 and a 52-week high of $82.02.

MAXIMUS (NYSE:MMS) last released its quarterly earnings data on Thursday, May 7th. The health services provider reported $0.43 earnings per share for the quarter, missing the consensus estimate of $0.82 by ($0.39). The company had revenue of $818.10 million for the quarter, compared to analysts’ expectations of $770.28 million. MAXIMUS had a net margin of 6.71% and a return on equity of 17.09%. The firm’s revenue for the quarter was up 11.1% on a year-over-year basis. During the same period in the previous year, the firm earned $0.96 earnings per share. As a group, equities research analysts anticipate that MAXIMUS, Inc. will post 3.09 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 31st. Investors of record on Friday, August 14th will be issued a $0.28 dividend. This represents a $1.12 dividend on an annualized basis and a dividend yield of 1.51%. The ex-dividend date is Thursday, August 13th. MAXIMUS’s payout ratio is 30.11%.

MMS has been the subject of a number of analyst reports. TheStreet raised MAXIMUS from a “c+” rating to a “b-” rating in a research report on Tuesday, July 28th. Raymond James upgraded MAXIMUS from a “market perform” rating to a “strong-buy” rating and set a $90.00 price target for the company in a report on Wednesday, July 8th. Finally, KeyCorp upgraded shares of MAXIMUS from a “sector weight” rating to an “overweight” rating and set a $80.00 price target on the stock in a research note on Wednesday, June 24th. Four research analysts have rated the stock with a hold rating, one has given a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $81.40.

MAXIMUS Profile

MAXIMUS, Inc provides business process services (BPS) to government health and human services programs worldwide. The company's Health Services segment offers various BPS, appeals, and assessments for state, provincial, and national government programs, including Medicaid, Children's Health Insurance Program, Affordable Care Act, Health Insurance British Columbia, Health Assessment Advisory Service contract, and Preadmission Screening and Resident Reviews.

Featured Story: Market Capitalization, Large-Caps, Mid-Caps, Small-Caps

Institutional Ownership by Quarter for MAXIMUS (NYSE:MMS)

Receive News & Ratings for MAXIMUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MAXIMUS and related companies with MarketBeat.com's FREE daily email newsletter.